<?xml version="1.0" encoding="UTF-8"?>
<p class="p">The ongoing (VITAL, NCT01169259) placebo-controlled trial, designed to examine major CV events, might clarify the utility of Lovaza, a drug formulation containing ethyl ester of EPA (465 mg) and DHA (375 mg), in primary prevention of CV disease [
 <xref rid="B48-marinedrugs-17-00374" ref-type="bibr" class="xref">48</xref>]. The randomized trial for evaluation in secondary prevention efficacy of combination therapyâ€“statin and EPA (RESPECT-EPA, UMIN000012069), a study involving statin-treated patients in Japan, and the effect of Vascepa (a preparation of EPA as ethyl ester) on improving coronary atherosclerosis in people with high triglyceride levels taking statin therapy trial (EVAPORATE, NCT02926027), which is examining changes in coronary plaque over 9 to 18 months, will provide further information on the effects of these agents. In addition, the statin residual risk reduction with Epanova in hiGh cardiovascular risk patients with hypertriglyceridemia (STRENGTH NCT02104817) is an ongoing trial that will be exploring residual cardiovascular risk reduction with 4 g daily of EPA/DHA (Epanova) versus corn oil in patients on statin therapy.
</p>
